<p>Liver Cancer is the sixth leading cause of morbidity and mortality worldwide. Effective treatment for HCC is challenging and heavily depends on early diagnosis. There is urgent need to identify a potent therapeutic target for HCC. Among various signaling pathways EGFR signaling cascade plays a crucial role in cancer cell growth and proliferation. Therefore, the inhibition of this pathway would be an effective treatment strategy for HCC. To investigate the inhibitory role of miRNA-1231 in EGFR pathway gene expression analysis was performed. Immunohistochemistry was also done for EGFR protein expressions analysis in HCC tissues. Interaction of EGFR with other genes was also analyzed using STRING database. Furthermore, molecular docking was conducted to evaluate the interaction between miRNA and EGFR mRNA. In this study, EGFR, AKT, mTOR, BCL2 and MDM2 genes were found to be significantly upregulated in HCC tissues while FOXO3, BIM and miRNA-1231 were downregulated (*<i>p &lt;</i> 0.05). Immunohistochemical staining also showed positive expressions of EGFR protein in HCC tissues as compared to non-cancerous tissues. PPI network analysis resulted in the generation of network showing strong interactions of EGFR with other genes. Additionally, Survival analysis of miRNA-1231 showed that the low expression of miRNA-1231 is related with poor outcome of HCC. Molecular docking analysis also indicated that there is strong interaction between miRNA-1231 and EGFR mRNA. We investigated that miRNA-1231 regulated EGFR pathway plays a major role in initiation and progression of HCC. Therefore, this data concluded that miRNA-1231 could be a potential prognostic marker as well as therapeutic target for HCC.</p>